CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
挽救性化疗方案与嵌合抗原 T 细胞受体疗法在复发/难治性弥漫大 B 细胞淋巴瘤中的比较效果：临床试验的网络荟萃分析
英文原题：Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.
查看英文原题
Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对于复发/难治性（R/R）弥漫性大B细胞淋巴瘤（DLBCL）在自体干细胞移植前的最佳挽救化疗方案（SC）仍不明确。此外，尽管CAR-T 细胞疗法最近被批准用于原发性难治性DLBCL，但缺乏头对头比较。
我们检索了MEDLINE、EMBASE和CENTRAL至2022年7月，纳入招募成人R/R DLBCL患者的随机试验，并进行网络荟萃分析（NMA）以评估SC和CAR-T 疗法的疗效。SC的NMA（6项试验，7种方案，n = 1831）表明，利妥昔单抗联合吉西他滨、地塞米松、顺铂（R-GDP）相比所比较的方案改善了OS和PFS。3项CAR-T 试验的NMA（n = 865）表明，axi-cel和liso-cel均相比标准治疗改善了PFS，OS无差异。
我们的结果表明，对于R/R DLBCL，R-GDP可能优于其他所比较的SC。随着CAR-T 试验数据的成熟，正在进行的比较生存分析需要更长的随访时间。
展开英文摘要原文
The optimal salvage chemotherapy regimen (SC) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) prior to autologous stem cell transplant remains unclear.
Moreover, although chimeric antigen receptor T cell (CAR-T) therapies were recently approved for primary refractory DLBCL, head-to-head comparisons are lacking.
We searched MEDLINE, EMBASE and CENTRAL to July 2022, for randomized trials that enrolled adult patients with R/R DLBCL and performed network meta-analyses (NMA) to assess the efficacy of SC and CAR-T therapies. NMA of SC (6 trials, 7 regimens, n = 1831) indicated that rituximab with gemcitabine, dexamethasone, cisplatin (R-GDP) improved OS and PFS over compared regimens. NMA of 3 CAR-T trials ( n = 865) indicated that both axi-cel and liso-cel improved PFS over standard of care, with no difference in OS.
Our results indicate that R-GDP may be preferred for R/R DLBCL over other SC compared. Longer follow-up is required for ongoing comparative survival analysis as data from CAR-T trials matures.
论文信息
- 作者
- Gong IY、Aminilari M、Landego I、Hueniken K、Zhou Q、Kuruvilla J、Hodgson DC
- 单位
- Department of Radiation Medicine, University of Toronto, Toronto, Ontario, Canada.Canada
- 文献类型
- 非美国政府资助研究 · 网状荟萃分析
- 期刊
- Leukemia & lymphoma2023 Oct
- 原文标识
- PubMed 37548344 · DOI 10.1080/10428194.2023.2234528
READING GUIDES
相关资料阅读指南
了解这条资料涉及的技术、疾病或试验登记信息，再回到原始来源核实。